What do systematic reviews say?

6 questions · 6 findings · 2 reviews · HIV/AIDS

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 6 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

An extended ZDV/3TC/LPV/r regimen administered to mothers vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Maternal Grade 3/4 Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants

It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes maternal Grade 3/4 Severe Adverse Events compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (very low certainty).

1 finding from 1 review

Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
RR 1.19 [0.83, 1.7]
1 study · 824 participants
Very low

Bae: AZT/3TC/NVP vs d4T/3TC/NVP

Maternal Grade 3/4 Severe Adverse Events · HIV‐Infected Pregnant Women With CD4<350

It is very uncertain whether jamisse (What to Start): AZT/3TC/NVP changes maternal Grade 3/4 Severe Adverse Events compared with d4T/3TC/NVP (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.58 [0.6, 4.12]
1 study · 146 participants
Very low

Bae: AZT/3TC/NVP vs AZT/3TC/NVP

Maternal Grade 3/4 Severe Adverse Events · HIV‐infected pregnant women

It is very uncertain whether jamisse (When to Start): AZT/3TC/NVP for CD4 250‐350 changes maternal Grade 3/4 Severe Adverse Events compared with AZT/3TC/NVP (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.18 [0.47, 2.97]
1 study · 146 participants
Very low

Bae: AZT/3TC/NVP vs AZT/3TC/NVP

Maternal Grade 3/4 Severe Adverse Events · HIV‐1 Infected Pregnant Women Who Have CD4>200 Compared with Those Who Have CD4<200 Cells/mm3

It is very uncertain whether phanuphak: AZT/3TC/NVP (PMTCT) changes maternal Grade 3/4 Severe Adverse Events compared with AZT/3TC/NVP (ART) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.98 [0.65, 6.03]
1 study · 244 participants
Very low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Maternal Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes maternal Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.09 [0.77, 1.53]
1 study · 824 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course Regimen

Maternal Grade 3/4 Severe Adverse Events Requiring Treatment Modification · HIV‐infected pregnant women

It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes maternal Grade 3/4 Severe Adverse Events Requiring Treatment… compared with other Short Course Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 25.33 [1.49, 430.51]
1 study · 250 participants
Very low